Literature DB >> 19439366

Effect of lipopolysaccharide on intranasal administration of liposomal Newcastle disease virus vaccine to SPF chickens.

Li-Ping Tseng1, Chwei-Jang Chiou, Chien-Chung Chen, Ming-Chung Deng, Tze-Wen Chung, Yi-You Huang, Der-Zen Liu.   

Abstract

In order to potentiate the low immunogenicity of the inactivated Newcastle disease virus immunized into chickens by mucosal route, liposomes as a drug delivery system and LPS (lipopolysaccharide) as an immuno-stimulator were evaluated. Here, we report a new nasal delivery system of inactivated Newcastle disease virus (NDV) vaccine. The intranasal vaccine was based on different lipids to form MLV (multi-lamellar vehicles) liposomes. The liposomes had combined carrier and adjuvant activities, which induced strong systemic (serum) and local (lung and nasal) humoral responses in SPF (specific-pathogen-free) chickens, and provided protective immunity. PC-Lip (phosphatidylcholine-liposome) elicited significant mucosal secretary immunoglobulin A (s-IgA) levels (p<0.05) in tracheal lavage fluid and serum IgG levels (p<0.05). In response to virulent viral challenge, birds treated with PBS (phosphate buffered saline) as control group died, whereas 80% of chickens which received PC-Lip, PC-Lip-LPS, PS-Lip (phosphatidylserine-liposome), and PS-Lip-LPS survived. HAI titers were 1:2560 in the PS-Lip-LPS group and 1:1280 in the PC-Lip, PC-Lip-LPS, and PS-Lip groups after two vaccinations. The results suggest that PC-Lip or PS-Lip might thus be suitable as a potential adjuvant for mucosal vaccination against NDV in chickens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19439366     DOI: 10.1016/j.vetimm.2009.04.009

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  8 in total

Review 1.  Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.

Authors:  Daniella Calderon-Nieva; Kalhari Bandara Goonewardene; Susantha Gomis; Marianna Foldvari
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

2.  Co-administration of toll-like receptor (TLR)-3 and 4 ligands augments immune response to Newcastle disease virus (NDV) vaccine in chicken.

Authors:  T R Kannaki; E Priyanka; M R Reddy
Journal:  Vet Res Commun       Date:  2019-08-24       Impact factor: 2.459

3.  Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.

Authors:  Angela Henderson; Katie Propst; Ross Kedl; Steven Dow
Journal:  Vaccine       Date:  2011-05-19       Impact factor: 3.641

4.  Preparation of mucosal nanoparticles and polymer-based inactivated vaccine for Newcastle disease and H9N2 AI viruses.

Authors:  Heba M El Naggar; Mohamed Sayed Madkour; Hussein Ali Hussein
Journal:  Vet World       Date:  2017-02-14

Review 5.  Newcastle disease vaccines-A solved problem or a continuous challenge?

Authors:  Kiril M Dimitrov; Claudio L Afonso; Qingzhong Yu; Patti J Miller
Journal:  Vet Microbiol       Date:  2016-12-16       Impact factor: 3.293

6.  Evaluation of a Lipopolysaccharide and Resiquimod Combination as an Adjuvant with Inactivated Newcastle Disease Virus Vaccine in Chickens.

Authors:  Bal Krishan Sharma; Saravanan Ramakrishnan; Abinaya Kaliappan; Mithilesh Singh; Ajay Kumar; Satyabrata Dandapat; Sohini Dey; Madhan Mohan Chellappa
Journal:  Vaccines (Basel)       Date:  2022-06-03

7.  Adjuvant activity of Sargassum pallidum polysaccharides against combined Newcastle disease, infectious bronchitis and avian influenza inactivated vaccines.

Authors:  Li-Jie Li; Ming-Yi Li; Yan-Tuan Li; Jing-Jing Feng; Feng-Qiang Hao; Zhang Lun
Journal:  Mar Drugs       Date:  2012-12       Impact factor: 5.118

8.  Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken.

Authors:  Javaid Jeelani Matoo; Khalid Bashir; Ajay Kumar; Narayanan Krishnaswamy; Sohini Dey; Madhan Mohan Chellappa; Saravanan Ramakrishnan
Journal:  Microb Pathog       Date:  2018-04-07       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.